{"id":"zoryve","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$13.7712/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$5,026","description":"ZORYVE 0.3% CREAM","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":{"setId":"ec1bb0d1-f38a-4080-831a-68791d1d1fdb","title":"ZORYVE (ROFLUMILAST) CREAM [ARCUTIS BIOTHERAPEUTICS, INC.]"},"ecosystem":[],"_scrapedAt":"2026-03-28T01:41:30.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07263230","phase":"PHASE2","title":"The Safety and Efficacy of Roflumilast Foam in HS","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-04-01","conditions":"Hidradenitis Suppurativa (HS)","enrollment":20},{"nctId":"NCT06631170","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-21","conditions":"Atopic Dermatitis (AD)","enrollment":354},{"nctId":"NCT06648772","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Plaque Psoriasis","enrollment":189},{"nctId":"NCT05763082","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2023-02-07","conditions":"Plaque Psoriasis","enrollment":414},{"nctId":"NCT06440473","phase":"PHASE4","title":"Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin","status":"RECRUITING","sponsor":"Rao Dermatology","startDate":"2024-05-28","conditions":"Healthy Skin","enrollment":3}],"_emaApprovals":[],"_faersSignals":[{"count":103,"reaction":"OFF LABEL USE"},{"count":73,"reaction":"DRUG INEFFECTIVE"},{"count":62,"reaction":"HEADACHE"},{"count":56,"reaction":"DIARRHOEA"},{"count":52,"reaction":"PRURITUS"},{"count":47,"reaction":"SKIN BURNING SENSATION"},{"count":37,"reaction":"PSORIASIS"},{"count":35,"reaction":"RASH"},{"count":32,"reaction":"NAUSEA"},{"count":30,"reaction":"INSOMNIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[{"date":"20240612","type":"SUPPL","sponsor":"ARCUTIS","applicationNumber":"NDA217242"},{"date":"20250522","type":"SUPPL","sponsor":"ARCUTIS","applicationNumber":"NDA217242"},{"date":"20231215","type":"ORIG","sponsor":"ARCUTIS","applicationNumber":"NDA217242"},{"date":"20231005","type":"SUPPL","sponsor":"ARCUTIS","applicationNumber":"NDA215985"},{"date":"20220729","type":"ORIG","sponsor":"ARCUTIS","applicationNumber":"NDA215985"},{"date":"20251004","type":"SUPPL","sponsor":"ARCUTIS","applicationNumber":"NDA215985"},{"date":"20240709","type":"SUPPL","sponsor":"ARCUTIS","applicationNumber":"NDA215985"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":15,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Zoryve","genericName":"Zoryve","companyName":"Padagis LLC","companyId":"padagis-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}